The breast cancer monoclonal antibodies market size has grown strongly in recent years. It will grow from $18.97 billion in 2023 to $20.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historical period can be attributed to several key factors. These include the escalating prevalence of breast cancer cases, an increased awareness regarding the efficacy of breast cancer monoclonal antibodies among both healthcare professionals and the general population, the demonstrated clinical effectiveness of these treatments, and a heightened demand for these therapies from patients. These elements collectively contributed to the growth and adoption of breast cancer monoclonal antibodies during this period, fostering their acceptance and utilization in breast cancer treatment protocols.
The breast cancer monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $27.8 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the upcoming period is expected to be driven by several factors. These include the emergence of new therapeutic targets for breast cancer treatment, the development and utilization of biosimilars in therapy, the exploration of combination therapies, a rise in global breast cancer incidence due to an aging population, and an increased focus on personalized medicine tailored to individual patient needs.
The expanding incidence of breast cancer globally is poised to fuel the growth of the breast cancer monoclonal antibody market. As of January 2023, statistics from the American Cancer Society revealed a notable increase in breast cancer cases, rising from 284,200 cases in 2021 to 300,590 in 2023, signifying a 5.76% growth. This upsurge in breast cancer prevalence globally is projected to serve as a significant driver propelling the demand for monoclonal antibodies specifically designed for breast cancer treatment.
Anticipated growth in the breast cancer monoclonal antibodies market is attributed to government initiatives and funding aimed at addressing breast cancer. Government initiatives encompass strategies, policies, and funding directed by governmental bodies to tackle breast cancer-related issues. Notably, in February 2023, the World Health Organization introduced the Global Breast Cancer Initiative Framework. This comprehensive framework aims to save 2.5 million lives by 2040 by advocating health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such governmental interventions and financial support are expected to be pivotal in driving the market for breast cancer monoclonal antibodies. Companies operating in the breast cancer monoclonal antibodies sector are strategically investing in targeted and combination therapies, proving to be more efficacious and less toxic than traditional treatment methods. Targeted cancer therapies involve drugs that selectively interfere with molecules specifically involved in cancer cell progression. This approach seeks to eliminate cancer cells while sparing normal cells, potentially offering more effectiveness compared to conventional chemotherapy and radiotherapy. Additionally, combination therapy, involving the use of multiple drugs for a single disease, has shown promising outcomes. For instance, in May 2022, F. Hoffmann-La Roche AG launched PHESGO, an innovative breast cancer treatment combining two monoclonal antibodies, Perjeta and Herceptin, along with hyaluronidase. Administered via subcutaneous injection in tandem with intravenous chemotherapy, PHESGO caters to early and metastatic breast cancer management, pioneering a fixed-dose formulation in oncology. This strategic investment in novel therapies indicates the direction of the breast cancer monoclonal antibodies market.
In November 2021, Pfizer Inc., a leading pharmaceutical and biotechnology company based in the United States, completed the acquisition of Trillium Therapeutics for a total of $2.22 billion. This strategic acquisition represents Pfizer's endeavor to broaden its range of biologics aimed at fortifying the innate immune system to combat various hematological malignancies and solid tumors effectively. Trillium Therapeutics, headquartered in Canada, is a biopharmaceutical company with a specialized focus on pioneering immunotherapies tailored for cancer treatment, including breast cancer.
Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Array BioPharma Inc., Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca PLC, Eddingpharm, Eisai Co. Ltd., Galena Biopharma Inc., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.
North America was the largest region in the breast cancer monoclonal antibodies market in 2023. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Two primary types of breast cancer monoclonal antibodies exist: naked mAbs and conjugated mAbs. Naked mAbs refer to antibodies devoid of drugs or radioactive substances, self-contained in their structure. This category constitutes the most common type of mAb used in combating cancer. The treatments involving breast cancer monoclonal antibodies encompass a spectrum including chemotherapy, surgery, radiation therapy, targeted therapy, biologic therapy, and hormone therapy. These treatments find utilization across various healthcare sectors, including hospitals and retail pharmacies, offering diverse therapeutic options for individuals combating breast cancer.
The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The breast cancer monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $27.8 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the upcoming period is expected to be driven by several factors. These include the emergence of new therapeutic targets for breast cancer treatment, the development and utilization of biosimilars in therapy, the exploration of combination therapies, a rise in global breast cancer incidence due to an aging population, and an increased focus on personalized medicine tailored to individual patient needs.
The expanding incidence of breast cancer globally is poised to fuel the growth of the breast cancer monoclonal antibody market. As of January 2023, statistics from the American Cancer Society revealed a notable increase in breast cancer cases, rising from 284,200 cases in 2021 to 300,590 in 2023, signifying a 5.76% growth. This upsurge in breast cancer prevalence globally is projected to serve as a significant driver propelling the demand for monoclonal antibodies specifically designed for breast cancer treatment.
Anticipated growth in the breast cancer monoclonal antibodies market is attributed to government initiatives and funding aimed at addressing breast cancer. Government initiatives encompass strategies, policies, and funding directed by governmental bodies to tackle breast cancer-related issues. Notably, in February 2023, the World Health Organization introduced the Global Breast Cancer Initiative Framework. This comprehensive framework aims to save 2.5 million lives by 2040 by advocating health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such governmental interventions and financial support are expected to be pivotal in driving the market for breast cancer monoclonal antibodies. Companies operating in the breast cancer monoclonal antibodies sector are strategically investing in targeted and combination therapies, proving to be more efficacious and less toxic than traditional treatment methods. Targeted cancer therapies involve drugs that selectively interfere with molecules specifically involved in cancer cell progression. This approach seeks to eliminate cancer cells while sparing normal cells, potentially offering more effectiveness compared to conventional chemotherapy and radiotherapy. Additionally, combination therapy, involving the use of multiple drugs for a single disease, has shown promising outcomes. For instance, in May 2022, F. Hoffmann-La Roche AG launched PHESGO, an innovative breast cancer treatment combining two monoclonal antibodies, Perjeta and Herceptin, along with hyaluronidase. Administered via subcutaneous injection in tandem with intravenous chemotherapy, PHESGO caters to early and metastatic breast cancer management, pioneering a fixed-dose formulation in oncology. This strategic investment in novel therapies indicates the direction of the breast cancer monoclonal antibodies market.
In November 2021, Pfizer Inc., a leading pharmaceutical and biotechnology company based in the United States, completed the acquisition of Trillium Therapeutics for a total of $2.22 billion. This strategic acquisition represents Pfizer's endeavor to broaden its range of biologics aimed at fortifying the innate immune system to combat various hematological malignancies and solid tumors effectively. Trillium Therapeutics, headquartered in Canada, is a biopharmaceutical company with a specialized focus on pioneering immunotherapies tailored for cancer treatment, including breast cancer.
Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Array BioPharma Inc., Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca PLC, Eddingpharm, Eisai Co. Ltd., Galena Biopharma Inc., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.
North America was the largest region in the breast cancer monoclonal antibodies market in 2023. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Two primary types of breast cancer monoclonal antibodies exist: naked mAbs and conjugated mAbs. Naked mAbs refer to antibodies devoid of drugs or radioactive substances, self-contained in their structure. This category constitutes the most common type of mAb used in combating cancer. The treatments involving breast cancer monoclonal antibodies encompass a spectrum including chemotherapy, surgery, radiation therapy, targeted therapy, biologic therapy, and hormone therapy. These treatments find utilization across various healthcare sectors, including hospitals and retail pharmacies, offering diverse therapeutic options for individuals combating breast cancer.
The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Breast Cancer Monoclonal Antibodies Market Characteristics3. Breast Cancer Monoclonal Antibodies Market Trends and Strategies31. Global Breast Cancer Monoclonal Antibodies Market Competitive Benchmarking32. Global Breast Cancer Monoclonal Antibodies Market Competitive Dashboard33. Key Mergers and Acquisitions in the Breast Cancer Monoclonal Antibodies Market
4. Breast Cancer Monoclonal Antibodies Market - Macro Economic Scenario
5. Global Breast Cancer Monoclonal Antibodies Market Size and Growth
6. Breast Cancer Monoclonal Antibodies Market Segmentation
7. Breast Cancer Monoclonal Antibodies Market Regional and Country Analysis
8. Asia-Pacific Breast Cancer Monoclonal Antibodies Market
9. China Breast Cancer Monoclonal Antibodies Market
10. India Breast Cancer Monoclonal Antibodies Market
11. Japan Breast Cancer Monoclonal Antibodies Market
12. Australia Breast Cancer Monoclonal Antibodies Market
13. Indonesia Breast Cancer Monoclonal Antibodies Market
14. South Korea Breast Cancer Monoclonal Antibodies Market
15. Western Europe Breast Cancer Monoclonal Antibodies Market
16. UK Breast Cancer Monoclonal Antibodies Market
17. Germany Breast Cancer Monoclonal Antibodies Market
18. France Breast Cancer Monoclonal Antibodies Market
19. Italy Breast Cancer Monoclonal Antibodies Market
20. Spain Breast Cancer Monoclonal Antibodies Market
21. Eastern Europe Breast Cancer Monoclonal Antibodies Market
22. Russia Breast Cancer Monoclonal Antibodies Market
23. North America Breast Cancer Monoclonal Antibodies Market
24. USA Breast Cancer Monoclonal Antibodies Market
25. Canada Breast Cancer Monoclonal Antibodies Market
26. South America Breast Cancer Monoclonal Antibodies Market
27. Brazil Breast Cancer Monoclonal Antibodies Market
28. Middle East Breast Cancer Monoclonal Antibodies Market
29. Africa Breast Cancer Monoclonal Antibodies Market
30. Breast Cancer Monoclonal Antibodies Market Competitive Landscape and Company Profiles
34. Breast Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Breast Cancer Monoclonal Antibodies Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on breast cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for breast cancer monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) by Product: Naked Mabs; Conjugated Mabs2) by Treatment: Chemotherapy; Surgery & Radiation Therapy; Targeted Therapy; Biologic Therapy; Hormone Therapy
3) by End-User: Hospitals; Retail Pharmacies
Key Companies Mentioned: Amgen Inc.; Mylan N.V.; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Amgen Inc.
- Mylan N.V.
- Merck & Co. Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Daiichi Sankyo Company Ltd.
- Biocad
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Array BioPharma Inc.
- Celldex Therapeutics Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche AG
- Immunomedics Inc.
- MacroGenics Inc.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Puma Biotechnology Inc.
- Seattle Genetics Inc.
- AstraZeneca plc
- Eddingpharm
- Eisai Co. Ltd.
- Galena Biopharma Inc.
- ImmunoGen Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Johnson & Johnson
- Mersana Therapeutics Inc.
- Immunocore Limited
- Immunovative Therapies Ltd.
